In chronic myelogenous leukemia (CML), protein phosphatase 2a (PP2a) activator FTY720 has been shown to process anti-leukemia activity, where synergistically genetic inhibition of BID and BIM could reverse the apoptosis induced by FTY720 (84). The gene discussed is BID; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.